 Shares of Kura Oncology NASDAQ: KURA -- a clinical-stage biopharmaceutical company that focuses on developing cancer treatments -- were up by 42.6 as of 1:49 p.m. EDT on Tuesday. The company did not report any news, but its stock is probably riding the wave of Syndax Pharmaceuticals NASDAQ: SNDX, another clinical-stage drugmaker whose shares are up by more than 50 as a result of positive data from a phase 1 clinical trial. Syndax released data from a phase 1 clinical trial for SNDX-5613 on Monday, saying that the data provided the first clinical evidence that disrupting the interaction between menin and MLL1 with our potent and selective inhibitor, SNDX-5613, can induce response in patients with genetically defined acute leukemias. 